Introduction
In its judgement of 04 October 2024 (C-21/23), the European Court of Justice (“ECJ”, “Court”) ruled, that the provisions of Chapter VIII of the GDPR, do not preclude national rules which grant undertakings the right to rely, on the basis of the prohibition of acts of unfair competition, on infringements of the substantive provisions of the GDPR allegedly committed by their competitors. The ECJ further ruled, that the data of a pharmacist’s customers, which are provided when ordering pharmacy-only but non-prescription medicines on an online sales platform, constitute “health data” within the meaning of Art. 4 (15) and Art. 9 GDPR (to that extent contrary to the Advocate General’s opinion of 25 April 2024).
Background
The plaintiff and the defendant in the main proceedings each operate a pharmacy. The defendant also holds a mail order license and sells its range of products, including pharmacy-only medicines, through the online sales platform Amazon Marketplace, which allows the seller to offer products directly to consumers. The plaintiff sought an injunction to prohibit the defendant selling pharmacy-only pharmaceuticals via the online sales platform. In the plaintiff’s opinion, such distribution constitutes an unfair commercial practice because the defendant was violating a statutory provision within the meaning of Section 3a of the German Act Against Unfair Competition (Gesetz gegen den unlauteren Wettbewerb – “UWG”).
The District Court upheld the claim. The Higher Regional Court dismissed the defendant’s appeal and ruled that the defendant’s sale of pharmacy-only medicines via Amazon Marketplace violates the provisions of the UWG, as this distribution involves the processing of health data within the meaning of Art. 9(1) GDPR, to which the customers have not explicitly consented. According to the Higher Regional Court, the provisions of the GDPR must be regarded as market conduct rules within the meaning of national competition law, with the result that the plaintiff, as a competitor, is entitled to claim injunctive relief based on national competition law by relying on an infringement of the provisions of the GDPR by the defendant.
The defendant then appealed to the German Federal Court of Justice (Bundesgerichtshof – “BGH”), in which it maintained its application for dismissal of the injunction. The BGH stated that the key factor for the decision is how Chapter VIII and Art. 9 of the GDPR are to be interpreted, and referred the following questions to the ECJ for a preliminary ruling:
- Do the rules in Chapter VIII GDPR preclude national rules which – alongside the powers of intervention of the supervisory authorities responsible for monitoring and enforcing the regulation and the options for legal redress for data subjects – empower competitors to bring proceedings for infringements of GDPR against the infringer before the civil courts on the basis of the prohibition of unfair commercial practices?
- Do the data of the customers of a pharmacist, who acts as a seller on an online sales platform, provide when ordering pharmacy-only but not prescription-only medicines (customer’s name, delivery address and information required for individualising the pharmacy-only medicine ordered) constitute data concerning health within the meaning of Article 9(1) GDPR?
Decision
First question (competitor’s right to bring injunction claims)
According to the ECJ, neither the wording of the provisions of Chapter VIII of the GDPR nor their context precludes competitors from bringing claims based on an infringement. On the contrary, where the infringement of the substantive provisions of the GDPR is likely to affect primarily the data subjects, it may also affect third parties. The Court notes that, in the context of the digital economy, access to personal data and the use that can be made of it are of considerable importance. Accordingly, in order to take account of real economic developments and to maintain fair competition, it may be necessary to take into account the rules on the protection of personal data when enforcing competition law and the rules on unfair commercial practices. The judgment recognises that the GDPR does not contain a specific opening clause, which expressly authorises Member States to allow competitors to seek an injunction to prevent an infringement of the GDPR. However, according to the Court, it is clear that the EU legislature, when adopting the GDPR, did not intend to achieve full harmonisation of the remedies available in the event of a breach of the provisions of the GDPR and, in particular, did not intend to exclude the possibility for competitors of an alleged infringer of the rules on the protection of personal data to bring an action under national law on the basis of the prohibition of unfair commercial practices.
Moreover, such an action for an injunction brought by a competitor could prove to be a particularly effective means of ensuring such protection, since it makes it possible to prevent numerous infringements of the rights of the data subjects (in this respect, the Court refers to its judgment of 28 April 2002, Meta Platforms Ireland, C-319/20, in which the Court ruled that the GDPR does not preclude national legislation which allows a consumer protection association to bring an action, in the absence of a mandate given to it for that purpose and irrespective of the infringement of specific rights of the data subjects).
In the light of the foregoing, the answer to the first question is that the provisions of Chapter VIII of the GDPR must be interpreted as not precluding a national law which, in addition to the powers of intervention of the supervisory authorities responsible for monitoring and enforcing that regulation, and the means of redress available to the data subjects, gives competitors of the alleged infringer the power to take action against the infringer before the civil courts on the basis of the prohibition of unfair commercial practices for infringements of the GDPR.
In the present case, it is therefore for the national court to determine whether the alleged infringement of the substantive provisions of the GDPR at issue in the main proceedings, if established, also constitutes an infringement of the prohibition of unfair commercial practices under the relevant national legislation.
Second question (scope of the protection of health data)
In the second part of its decision, the ECJ once again interpreted the term ‘special categories of personal data’ and, in this case specifically the term health data (Art. 4 no. 15 GDPR), very broadly. The Advocate General in its Opinion on the case had assumed that it is not possible to deduce the state of health of the customer with sufficient probability from orders of pharmacy-only but non-prescription medicines and therefore had found that such information is not health data.
The ECJ has now decided otherwise. The Court ruled that the provisions of the GDPR cannot be interpreted as meaning that the processing of personal data that only indirectly reveals sensitive information about a natural person would be exempt from the increased protection. For personal data to be classified as health data within the meaning of Article 9(1) of the GDPR, it is sufficient that the health of the data subject can be inferred by association or deduction. The Court affirms that the data provided by a customer when ordering pharmacy-only medicines via an online platform can be used to infer, by association or deduction, the health status of the data subject, since the order establishes a link between a medicinal product, its therapeutic indications and uses, and an identified natural person or a person who can be identified by information such as his or her name or delivery address.
Moreover, the prohibition on processing health data shall apply in principle, regardless of whether the information disclosed by the processing in question is accurate or not, and regardless of whether the data controller acts with the aim of obtaining information falling within one of the special categories referred to in Article 9(1) of the GDPR. Consequently, the information provided by customers when ordering non-prescription medicines online constitutes health data, even if those medicines are only intended for those customers with a certain probability and not with absolute certainty. In this context, the Court also mentions the possibility that the order data may allow conclusions about the health of third parties (e.g. by means of a different delivery address).
The court of the main proceedings will therefore have to decide whether the processing of health data of the customers of the defendant is permissible on the basis of one of the exceptions in Article 9(2) of the GDPR – in particular, because the data subject has given explicit informed consent, or whether the processing is permissible on the basis of Article 9(2)(h) of the GDPR because it is necessary for the purposes of health care and on the basis of Union or Member State law or pursuant to contract with a health professional .
Practical note
This is the third decision by the ECJ that allows actors other than data protection supervisory authorities to take legal action against controllers: in addition to the Meta Platforms decision of April 2022 mentioned above (C-319/20), in July this year, the ECJ clarified that the right of a consumer protection association to challenge the infringement of a data subject’s right “occurring in the course of processing” also extends to information obligations pursuant Articles 12(1) and 13(1) GDPR (C-752/22).
These rulings have significant consequences – they not only increase compliance risks, but also legal defense costs. In practice, consumer protection organisations – out of ignorance or lack of knowledge of business contexts – often take a more dogmatic approach than the competent data protection supervisory authority.
With the competitors, further inexperienced players are now entering the ring. Unlike in the past, it can be assumed that going forward, competitors will make use of the right to sue for injunctive relief if a controller is, in its view, violating the provisions of the GDPR and this is deemed unfair within the meaning of national competition law. As the acts against unfair competition are based on the EU Directive 2005/29/EC and therefore largely harmonized within the European Union, the ECJ’ decision is likely to affect all data controllers in the European Union.
Accordingly, in order to identify potential shortcomings that could be the subject of a competitor’s claim, controllers are well advised to review their existing processes in light of their specific business model. With respect to the potential processing of health information, a careful assessment is necessary. In particular, the question arises as to which constellations the extensive interpretation of the ECJ still covers in relation to health data – for example, dietary supplements. Or whether – as we believe – it should remain limited to pharmacy-only medicines.
Furthermore, this aspect should be considered in the planning of future business activities in order to avoid a cease-and-desist order.
[View source.]
